High serum fasting peptide YY (3-36) is associated with obesity-associated insulin resistance and type 2 diabetes

Regulatory Peptides

Volumn 170, Issue 1-3, 2011, Pages 38-42

  Ukkola, Olavi H ^a,b   Puurunen, Veli Pekka ^a   Piira, Olli Pekka ^a   Niva, Jarkko T ^a   Lepojärvi, E Samuli ^a   Tulppo, Mikko P ^c   Huikuri, Heikki V ^a  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c Verve   (Finland)

Author keywords

Gastro entero pancreatic factors; Insulin sensitivity; Weight regulation and obesity

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; ORAL ANTIDIABETIC AGENT; PEPTIDE YY [3-36]; TRIACYLGLYCEROL;

AGED; ARTICLE; BODY MASS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FASTING; HUMANS; INSULIN; INSULIN RESISTANCE; OBESITY; PEPTIDE YY;

EID: 79959697014     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2011.05.006     Document Type: Article

References (23)

1. Tatemoto K., Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 1980, 285:417-418.
2. Adrian T.E., Ferri G.L., Bacarese-Hamilton A.J., Fuessl H.S., Polak J.M., Bloom S.R. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985, 89:1070-1077.
3. Mentlein R., Dahms P., Grandt D., Krüger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993, 49:133-144.
4. Batterham R.L., Heffron H., Kapoor S., Chivers J.E., Chandarana K., Herzog H., et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 2006, 4:223-233.
5. Grandt D., Schimiczek M., Beglinger C., Layer P., Goebell H., Eysselein V.E., et al. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 1994, 51:151-159.
6. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002, 418:650-654.
7. Pittner R.A., Moore C.X., Bhavsar S.P., Gedulin B.R., Smith P.A., Jodka C.M., et al. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 2004, 28:963-971.
8. Tschöp M., Castañeda T.R., Joost H.G., Thöne-Reineke C., Ortmann S., Klaus S., et al. Physiology: does gut hormone PYY3-36 decrease food intake in rodents?. Nature 2004, 8:430. (6996).
9. Boey D., Lin S., Karl T., Baldock P., Lee N., Enriquez R., et al. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 2006, 49:1360-1370.
10. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003, 349:941-948.
11. Roth C.L., Enriori P.J., Harz K., Woelfle J., Cowley M.A., Reinehr T. Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss. J Clin Endocrinol Metab 2005, 90:6386-6391.
12. Stock S., Leichner P., Wong A.C., Ghatei M.A., Kieffer T.J., Bloom S.R., et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin Endocrinol Metab 2005, 90:2161-2168.
13. Kim B.J., Carlson O.D., Jang H.J., Elahi D., Berry C., Egan J.M. Peptide YY is secreted after oral glucose administration in a gender-specific manner. J Clin Endocrinol Metab 2005, 90:6665-6671.
14. Pfluger P.T., Kampe J., Castaneda T.R., Vahl T., D'Alessio D.A., Kruthaupt T., et al. Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. J Clin Endocrinol Metab 2007, 92:583-588.
15. Karra E., Chandarana K., Batterham R.L. The role of peptide YY in appetite regulation and obesity. J Physiol 2009, 587:19-25.
16. World Health Organization: Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1. Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999 (publ. no. WHO/NCD/NCS/99.2).
17. Jackson E.K., Zhang M., Liu W., Mi Z. Inhibition of renal dipeptidyl peptidase IV enhances peptide YY1-36-induced potentiation of angiotensin II-mediated renal vasoconstriction in spontaneously hypertensive rats. J Pharmacol Exp Ther 2007, 323:431-437.
18. English P.J., Ashcroft A., Patterson M., Dovey T.M., Halford J.C., Harrison J., et al. Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes. Diabetologia 2006, 49:2219-2221.
19. Carey D.G., Jenkins A.B., Campbell L.V., Freund J., Chisholm D.J. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996, 45:633-638.
20. Laakso M. How good a marker is insulin level for insulin resistance?. Am J Epidemiol 1993, 137:959-965.
21. Boey D., Sainsbury A., Herzog H. The role of peptide YY in regulating glucose homeostasis. Peptides 2007, 28:390-395.
22. Boey D., Heilbronn L., Sainsbury A., Laybutt R., Kriketos A., Herzog H., et al. Low serum PYY is linked to insulin resistance in first-degree relatives of subjects with type 2 diabetes. Neuropeptides 2006, 40:317-324.
23. le Roux C.W., Batterham R.L., Aylwin S.J., Patterson M., Borg C.M., Wynne K.J., et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006, 147:3-8.